1093 — CSPC Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapNeutral

Annual income statement for CSPC Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	HKAS	HKAS	HKAS	HKAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	24,942	27,867	30,937	31,450	29,009
Cost of Revenue
Gross Profit	18,685	21,135	22,256	22,177	20,299
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	18,552	21,035	23,314	23,981	23,297
Operating Profit	6,390	6,832	7,623	7,469	5,712
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	6,391	6,847	7,582	7,389	5,579
Provision for Income Taxes
Net Income After Taxes	5,229	5,688	6,232	6,073	4,339
Minority Interest
Net Income Before Extraordinary Items
Net Income	5,160	5,605	6,091	5,873	4,328
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	5,160	5,605	6,091	5,873	4,328
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.41	0.471	0.513	0.497	0.37
Dividends per Share